Cargando…
Tyrosine Kinase Inhibitor Pazopanib Inhibits Platelet Procoagulant Activity in Renal Cell Carcinoma Patients
Pazopanib is an angiostatic tyrosine kinase inhibitor (TKI) presently used for cancer treatment, particularly in patients with renal cell carcinoma (RCC). This treatment can be accompanied by mild bleeding as an adverse effect. Given the role of protein tyrosine kinases in platelet activation proces...
Autores principales: | Tullemans, Bibian M. E., Nagy, Magdolna, Sabrkhany, Siamack, Griffioen, Arjan W., oude Egbrink, Mirjam G. A., Aarts, Maureen, Heemskerk, Johan W. M., Kuijpers, Marijke J. E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6232667/ https://www.ncbi.nlm.nih.gov/pubmed/30460241 http://dx.doi.org/10.3389/fcvm.2018.00142 |
Ejemplares similares
-
Platelets as messengers of early-stage cancer
por: Sabrkhany, Siamack, et al.
Publicado: (2021) -
Age- and gender-matched controls needed for platelet-based biomarker studies
por: Sabrkhany, Siamack, et al.
Publicado: (2022) -
Multiparameter Evaluation of the Platelet-Inhibitory Effects of Tyrosine Kinase Inhibitors Used for Cancer Treatment
por: Tullemans, Bibian M. E., et al.
Publicado: (2021) -
Quantitative and qualitative changes in platelet traits of sunitinib-treated patients with renal cell carcinoma in relation to circulating sunitinib levels: a proof-of-concept study
por: Tullemans, Bibian M. E., et al.
Publicado: (2022) -
The Analysis of Platelet-Derived circRNA Repertoire as Potential Diagnostic Biomarker for Non-Small Cell Lung Cancer
por: D’Ambrosi, Silvia, et al.
Publicado: (2021)